{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:11:51Z","timestamp":1769598711102,"version":"3.49.0"},"reference-count":10,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"DOI":"10.1182\/blood.2024028105","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T15:31:28Z","timestamp":1746718288000},"page":"2105-2106","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["From prognostication to precision in acute myeloid leukemia"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6189-8067","authenticated-orcid":false,"given":"Christopher S.","family":"Hourigan","sequence":"first","affiliation":[{"name":"Fralin Biomedical Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"19","key":"2025050811312294900_bib1","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2024025154","article-title":"Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD\u2013mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood"},{"issue":"15","key":"2025050811312294900_bib2","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2025050811312294900_bib3","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2025050811312294900_bib4","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"issue":"4","key":"2025050811312294900_bib5","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.22.00715","article-title":"Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia","volume":"41","author":"Grob","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"2025050811312294900_bib6","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1182\/blood.2022016567","article-title":"Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical\u00a0outcome","volume":"140","author":"Loo","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2025050811312294900_bib7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact\u00a0of conditioning intensity of allogeneic transplantation for acute myeloid leukemia\u00a0with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2025050811312294900_bib8","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jamaoncol.2024.0985","article-title":"Measurable residual FLT3 internal tandem duplication before allogeneic transplant for acute myeloid leukemia","volume":"10","author":"Dillon","year":"2024","journal-title":"JAMA Oncol"},{"issue":"10","key":"2025050811312294900_bib9","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1038\/s41375-019-0483-z","article-title":"getITD for FLT3-ITD-based MRD monitoring in AML","volume":"33","author":"Bl\u00e4tte","year":"2019","journal-title":"Leukemia"},{"key":"2025050811312294900_bib10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41409-024-02444-7","article-title":"Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia","volume":"60","author":"Hegde","year":"2025","journal-title":"Bone Marrow Transplant"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/19\/2105\/2372454\/blood_bld-2024-028105-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/19\/2105\/2372454\/blood_bld-2024-028105-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T15:31:30Z","timestamp":1746718290000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/19\/2105\/537062\/From-prognostication-to-precision-in-acute-myeloid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":10,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024028105","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]}}}